导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 37.81% | 70/4773 |
| 近一周 | 0.14% | 1132/5467 |
| 近一月 | -6.39% | 3100/5421 |
| 近一季 | -21.32% | 4929/5238 |
| 近半年 | 34.12% | 77/4931 |
| 近一年 | 55.36% | 54/4400 |
| 近两年 | 258.26% | 46/2954 |
| 近三年 | 247.73% | 6/2253 |
| 成立以来 | 140.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.47% 1262/4961 |
81.35% 176/5312 |
- - |
- - |
| 2025 | 99.40% 21/4813 |
-2.88% 3001/3635 |
6.46% 449/4076 |
80.01% 2/4524 |
7.13% 316/4813 |
| 2024 | 24.10% 305/3463 |
0.46% 973/2808 |
9.54% 48/3014 |
9.84% 2663/3129 |
2.67% 909/3463 |
| 2023 | 16.30% 31/2656 |
24.47% 103/2280 |
8.33% 19/2385 |
-12.91% 2130/2515 |
-0.96% 273/2655 |
| 2022 | -37.57% 1757/2207 |
-28.16% 1805/1919 |
3.32% 1172/2016 |
-19.59% 1792/2113 |
4.61% 531/2208 |
| 2021 | 6.49% 513/1822 |
-16.36% 1194/1255 |
21.53% 133/1330 |
-10.21% 1217/1466 |
16.68% 51/1822 |
| 2020 | 19.22% 736/1250 |
0.32% 164/1028 |
28.06% 117/1067 |
-5.68% 1114/1164 |
-1.61% 1111/1184 |
| 2019 | - - |
- - |
- - |
- - |
1.61% 875/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华夏中证5G通信主题ETF VS. 长安沪深300非周期A(740101) |